DLGAP5 and hepatocellular carcinoma: DLGAP5 is significantly upregulated in 76.4 % of HCC specimens compared to adjacent liver tissue and is overexpressed in 25 % of AFP-negative cases, suggesting its potential as a novel biomarker.